Department of Psychology, Louisiana State University, Baton Rouge, LA 70803-5501, USA.
Res Dev Disabil. 2010 Nov-Dec;31(6):1135-41. doi: 10.1016/j.ridd.2010.07.003. Epub 2010 Aug 8.
Clozapine has been approved in the United States since 1990 for refractory or treatment resistant schizophrenia in the general population. However, as with many other antipsychotic medications, it is being prescribed for reasons other than those indicated. Among individuals with intellectual disabilities, clozapine is increasingly being prescribed to treat behavioral problems, although the empirical evidence for such a practice is lacking. This review was undertaken as an attempt to summarize the available studies regarding the use of clozapine for behavioral purposes among individuals with intellectual disabilities. Findings of our review suggest that the effectiveness of clozapine in targeting challenging behaviors among individuals with intellectual disabilities is relatively inconclusive at present. We discuss reasons why these limitations exist and offer some solutions to help alleviate these limitations.
氯氮平自 1990 年以来已获美国批准，用于一般人群中难治性或治疗抵抗性精神分裂症。然而，与许多其他抗精神病药物一样，它的使用超出了适应证。在智力残疾者中，氯氮平越来越多地被用于治疗行为问题，尽管缺乏这种做法的经验证据。开展本次综述的目的是试图总结目前有关氯氮平用于智力残疾者行为目的的研究。本综述的结果表明，氯氮平针对智力残疾者挑战性行为的疗效目前尚不确定。我们讨论了存在这些局限性的原因，并提供了一些解决方案来帮助减轻这些局限性。
